Baxter International stock hits 52-week low at 23.64 USD

Published 31/07/2025, 14:34
Baxter International stock hits 52-week low at 23.64 USD

Baxter International (NYSE:BAX) stock has reached a new 52-week low, trading at 23.64 USD. This milestone reflects a significant downturn for the company, which has seen its stock price decline by 22.1% over the past year. Despite the challenges, InvestingPro data shows the healthcare equipment giant maintains a solid current ratio of 2.02 and has sustained dividend payments for 55 consecutive years. The healthcare company’s performance has been under scrutiny as market conditions and internal challenges have contributed to its declining stock value. While the company posted negative earnings in the last twelve months, InvestingPro analysts forecast a return to profitability this year, with revenue growth of 15.36%. Investors are closely monitoring Baxter’s strategic responses to these pressures, as the company seeks to navigate this challenging period and restore confidence in its financial health. According to InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels, suggesting potential upside for patient investors.

In other recent news, Baxter International announced the appointment of Andrew Hider as its new CEO, effective by September 2025. This leadership change has prompted Goldman Sachs to reiterate its Conviction Buy rating with a price target of $37.00, while Citi and BofA Securities have maintained their Neutral ratings with price targets of $34.00 and $40.00, respectively. UBS also kept its Neutral rating, setting a $35.00 price target, as the company continues to navigate its CEO transition. Additionally, Baxter has secured a $2.2 billion credit agreement, enhancing its borrowing capacity from a previously established $2 billion facility. This new five-year agreement allows for borrowing in multiple currencies and provides an option to increase the total commitment to $3.3 billion. The agreement replaces a €200 million credit facility that was terminated. Baxter’s recent developments reflect its strategic efforts to maintain growth and financial flexibility.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.